MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Interaction of dietary protein with levodopa in Parkinson disease.

B. Sharma, A. Rassmann, T. Virmani (Little Rock, AR, USA)

Meeting: 2017 International Congress

Abstract Number: 720

Keywords: Parkinsonism

Session Information

Date: Tuesday, June 6, 2017

Session Title: Therapy in Movement Disorders

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: To study the effect of dietary protein on levodopa effectiveness in Parkinson disease (PD) patients.

 

Background: Levodopa transport across the blood brain barrier is modulated by large neutral amino acids and thereby dietary protein has been suggested to interfere with levodopa effectiveness. Due to this PD patients are commonly advised to dose levodopa on an empty stomach. In a retrospective study of over 1000 patients, Virmani et al. [1] suggested that protein interaction with levodopa occurred in <15% of PD patients who had earlier disease onset and positive family history of PD.

 

Methods: Here we prospectively assessed the interaction between protein diets and levodopa causing motor symptom fluctuations in patients with PD. After IRB approval, subjects filled a questionnaire detailing their motor symptoms, medications used, presence and severity of motor fluctuations, and effect of dietary protein on levodopa effectiveness. Motor fluctuations due to protein interaction with levodopa were defined as leading to (i) longer time to levodopa effectiveness, (ii) reduced benefit or duration of benefit, (iii) dose failures or (iv) earlier wearing off from a previously effective dose. Statistical analysis was performed using SPSS 22 (IBM).

 

Results: 44 patients participated to date, with average motor onset at 60.5±12.3 years and disease duration of 8.4±6.6 years. 25% on levodopa reported motor fluctuation with high protein meals. These patients trended towards being younger at motor onset (55.9±12.9 vs 62.0±9.5; p=0.11), had started levodopa at an earlier age (57±10.2 vs 66±7.3; p<0.01), and were on equivalent maximum daily levodopa doses (857±382 vs 890±190 mg/day; p=0.78) for similar duration (2.9±5.4 vs 4.3±3.6 years; p=0.39). A higher percentage reported lifetime dopamine agonist use (82% vs 30%; p<0.05) and were also concurrently on a dopamine agonist with levodopa (50% vs 10%; p<0.05). Percent reporting family members with PD were equivalent (36% vs 39%; p=0.86).

Conclusions: In our cohort, 25% of patients with PD on levodopa reported protein interaction with levodopa and were possibly younger at disease onset, had started levodopa at an earlier age and a higher fraction had been on, and were concurrently on dopamine agonists. This suggests that counseling patients to dose levodopa on an empty stomach may not be warranted early in the disease.

 

References: 1.            Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease. J Clin Mov Disord 2016;3:8.

To cite this abstract in AMA style:

B. Sharma, A. Rassmann, T. Virmani. Interaction of dietary protein with levodopa in Parkinson disease. [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/interaction-of-dietary-protein-with-levodopa-in-parkinson-disease/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/interaction-of-dietary-protein-with-levodopa-in-parkinson-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley